In an Aug. 28, 2013, announcement, the Dutch biotechnology company announced favorable results for drisapersen and a new grant for continuing development of PRO045
posted on August 30, 2013 - 5:00am
Update (Oct. 15, 2013): In an Oct. 15, 2013, webinar, Prosensa announced preliminary results for the phase 1-2 trial of PRO044, designed to target exon 44 of the dystrophin gene. Dystrophin production that is believed to have occurred in response to the drug was seen in 12 out of 21 muscle biopsies that could be evaluated. No drug-related serious adverse events have been reported.
Investigators presented intriguing data from a trial of an experimental exon skipping drug for Duchenne muscular dystrophy, at the 2010 American Academy of Neurology meeting
posted on April 14, 2010 - 3:21am
The multinational pharmaceutical company GlaxoSmithKline (GSK) and the Dutch biotechnology company Prosensa announced "intriguing results" following a 12-person trial of an experimental "exon skipping" therapeutic for Duchenne muscular dystrophy (DMD).